Semaglutide is a synthetic long-acting glucagon-like peptide-1 (GLP-1) receptor agonist derived from native GLP-1(7-37) with three key modifications — Aib8, Arg34 and lysine-26 C18 fatty-di-acid acylation via a γGlu-2xOEG spacer.
The modifications confer DPP-4 resistance and reversible albumin binding, extending plasma half-life to approximately one week. Semaglutide is one of the most extensively studied compounds in the GLP-1 class.
Oxford Research Peptides supplies Semaglutide strictly as a lyophilised reference standard for in-vitro laboratory research; approved Semaglutide medicines are prescription therapeutics regulated by the MHRA in the United Kingdom.
Semaglutide is the reference long-acting GLP-1 receptor agonist against which every subsequent incretin analogue is benchmarked.